Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
Debating Point
Value-based pricing, the future of reimbursement?
As drug funders across developed markets search for ways to pay for increasingly expensive therapies while under pressure to bring new products to market rapidly, more think they will find answers in so-called 'value-based pricing' but not everyone agrees.
Approvals Action
TGA approves Enbrel competitor
The TGA has approved MSD's Brenzys, its biosimilar competitor for Pfizer's blockbuster Enbrel.
Pipeline Monitor
Opdivo in line for label expansion
BMS's Opdivo is on track to add another cancer to its growing list of approvals.
Company Snapshot
Pfizer: the giant powers on
Pfizer's Australian operations go under the microscope.